A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (what the body does to the
medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in
healthy participants and in patients with moderate hepatic impairment after administration of
a single 400 mg dose of TMC207.